SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment
ConclusionsPost-marketing data showed that SGLT-2i was significantly associated with higher reporting of euDKA/DKA. Although euDKA/DKA is rare, clinicians should be aware of SGLT-2i-associated euDKA/DKA events.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
More News: Canagliflozin | Dapagliflozin | Databases & Libraries | Diabetes | Empagliflozin | Endocrinology | Forxiga | Invokana | Jardiance | Sodium